Dianthus Therapeutics (DNTH) director exercises options and sells 2,777 shares under 10b5-1 plan
Rhea-AI Filing Summary
Dianthus Therapeutics (DNTH) director Simon Read exercised stock options for 2,777 shares of common stock at an exercise price of $18.36 per share, converting a Stock Option (Right to Buy) into common shares. On the same date, he reported six open-market sales totaling 2,777 shares at per-share prices including $107.11, $108.17, $108.95, $109.96, $111.05 and $111.77, each disclosed as a weighted average price across multiple trades within specified ranges. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Following the option exercise, Read reported 22,223 option shares remaining under the same award, which vests in three equal annual installments, subject to continued service and an expiration date of May 22, 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 2,777 shares ($253K approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
Read Simon
Role
Director
Sold
2,777 shs ($304K)
Approx. gross sale proceeds
$304K
Approx. exercise cost
$51K
Approx. pre-tax spread
$253K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F8 | 2,777 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,777 | $18.36 | $51K |
| Sale | Common Stock F1, F2 | 70 | $107.11 | $7K |
| Sale | Common Stock F1, F3 | 737 | $108.17 | $80K |
| Sale | Common Stock F1, F4 | 831 | $108.95 | $91K |
| Sale | Common Stock F1, F5 | 272 | $109.96 | $30K |
| Sale | Common Stock F1, F6 | 470 | $111.05 | $52K |
| Sale | Common Stock F1, F7 | 397 | $111.77 | $44K |
Holdings After Transaction:
Stock Option (Right to Buy) — 22,223 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (8)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.50 to $107.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.54 to $108.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.55 to $110.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.56 to $111.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.57 to $111.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F8. The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Options exercised: 2,777 shares
Option exercise price: $18.36 per share
Total shares sold: 2,777 shares
+5 more
8 metrics
Options exercised
2,777 shares
Stock Option (Right to Buy) converted into common stock on 2026-08-10
Option exercise price
$18.36 per share
Exercise price of Stock Option (Right to Buy) underlying 2,777 shares
Total shares sold
2,777 shares
Aggregate of six open-market sales of DNTH common stock on 2026-08-10
Sale tranche price example
$107.11 per share
Weighted average price for 70 shares sold, with trades from $106.50 to $107.27
Highest reported sale price
$111.77 per share
Weighted average for 397 shares sold, with trades from $111.57 to $111.80
Remaining option shares
22,223 shares
Shares underlying the remaining Stock Option position after exercise
Option expiration
May 22, 2035
Expiration date of the Stock Option (Right to Buy)
10b5-1 plan adoption date
May 8, 2026
Date Rule 10b5-1 trading plan governing these trades was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"underlying this stock option award vest as to one-third of the shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date": "2035-05-22""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did DNTH director Simon Read report in this Form 4?
Simon Read reported exercising options for 2,777 DNTH shares at $18.36 per share and selling 2,777 common shares in multiple open-market transactions on August 10, 2026, under a Rule 10b5-1 trading plan.
What options did Simon Read exercise in Dianthus Therapeutics (DNTH)?
He exercised a Stock Option (Right to Buy) for 2,777 common shares at an exercise price of $18.36 per share, reducing that option position and increasing his common stock before the same-day sales.
How were the DNTH sale prices reported in Simon Read’s Form 4?
Each sale line item shows a weighted average price, with footnotes explaining that shares were sold in multiple transactions within specific price ranges (for example, $106.50–$107.27), and detailed trade data is available on request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
